CRISPR Therapeutics ($CRSP) has endured a tough year since gaining several important regulatory approvals for its ...

Cancer remains one of the most challenging diseases to treat, but in recent years, researchers have made remarkable progress ...

Alzheimer’s disease, the most common form of dementia, affects millions of people worldwide, slowly robbing them of their ...

New research from Karolinska Institutet shows that long-term sex hormone treatment in transgender individuals can lead to significant changes in body composition and risk factors for cardiovascular ...

The U.S. Food and Drug Administration is weighing the need for a regulatory action on bluebird bio's gene therapy for a rare ...

Proliferative vitreoretinopathy (PVR) is an eye condition that leads to blindness and can currently only be addressed with ...

Once inside the body, HIV persists because of its remarkable ability to hide within healthy CD4 T cells, where it can lie ...

Sarepta will pay Arrowhead Pharmaceuticals $500 million upfront, make a $325 million equity investment, plus pay $250 million over five years, and more.

Discover various promising treatments in development to address the unmet needs of people with Charcot–Marie–Tooth disease.

Used in conjunction with the oral sonosensitizing agent 5-ALA, the sonodynamic therapy led to a median OS of 15.7 months in ...

“Every year, NobleCon showcases emerging growth companies from a variety of industries to a relevant investor audience,” said Dr. Musunuri. “I look forward to sharing an update on our clinical ...

PTC Therapeutics may reeling from the failure of its amyotrophic lateral sclerosis (ALS) drug utreloxastat yesterday, but the ...